SURMODICS INC (SRDX)
US8688731004 - Common Stock
Overall SRDX gets a fundamental rating of 5 out of 10. We evaluated SRDX against 193 industry peers in the Health Care Equipment & Supplies industry. SRDX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SRDX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRDX was profitable.
In the past year SRDX had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: SRDX reported negative net income in multiple years.
SRDX had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of SRDX (7.39%) is better than 87.56% of its industry peers.
Looking at the Return On Equity, with a value of 10.90%, SRDX belongs to the top of the industry, outperforming 87.05% of the companies in the same industry.
SRDX has a Return On Invested Capital of 9.32%. This is amongst the best in the industry. SRDX outperforms 89.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.39% | ||
| ROE | 10.9% | ||
| ROIC | 9.32% |
ROA(3y)-5.3%
ROA(5y)-2.1%
ROE(3y)-7.82%
ROE(5y)-3.28%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SRDX's Profit Margin of 9.45% is amongst the best of the industry. SRDX outperforms 83.42% of its industry peers.
SRDX's Operating Margin of 13.50% is amongst the best of the industry. SRDX outperforms 84.97% of its industry peers.
The Gross Margin of SRDX (79.11%) is better than 90.67% of its industry peers.
SRDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.5% | ||
| PM (TTM) | 9.45% | ||
| GM | 79.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.05%
GM growth 5Y-0.39%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SRDX is destroying value.
Compared to 1 year ago, SRDX has more shares outstanding
SRDX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, SRDX has a worse debt to assets ratio.
2.2 Solvency
SRDX has an Altman-Z score of 7.01. This indicates that SRDX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SRDX (7.01) is better than 83.42% of its industry peers.
SRDX has a debt to FCF ratio of 1.31. This is a very positive value and a sign of high solvency as it would only need 1.31 years to pay back of all of its debts.
SRDX's Debt to FCF ratio of 1.31 is amongst the best of the industry. SRDX outperforms 89.64% of its industry peers.
SRDX has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.24, SRDX perfoms like the industry average, outperforming 49.22% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | 1.31 | ||
| Altman-Z | 7.01 |
ROIC/WACC0.94
WACC9.93%
2.3 Liquidity
SRDX has a Current Ratio of 4.39. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 4.39, SRDX is doing good in the industry, outperforming 64.77% of the companies in the same industry.
SRDX has a Quick Ratio of 3.59. This indicates that SRDX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.59, SRDX is doing good in the industry, outperforming 66.32% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.59 |
3. Growth
3.1 Past
SRDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.67%, which is quite impressive.
The earnings per share for SRDX have been decreasing by -21.08% on average. This is quite bad
Looking at the last year, SRDX shows a very strong growth in Revenue. The Revenue has grown by 38.84%.
SRDX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.28% yearly.
EPS 1Y (TTM)174.67%
EPS 3Y7.72%
EPS 5Y-21.08%
EPS growth Q2Q117.5%
Revenue 1Y (TTM)38.84%
Revenue growth 3Y11.79%
Revenue growth 5Y10.28%
Revenue growth Q2Q17.49%
3.2 Future
The Earnings Per Share is expected to decrease by -0.70% on average over the next years.
SRDX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.73% yearly.
EPS Next Y-740.34%
EPS Next 2Y-99.21%
EPS Next 3Y-0.7%
EPS Next 5YN/A
Revenue Next Year-8.55%
Revenue Next 2Y2.01%
Revenue Next 3Y5.73%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.13, the valuation of SRDX can be described as expensive.
77.72% of the companies in the same industry are more expensive than SRDX, based on the Price/Earnings ratio.
SRDX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 28.53, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for SRDX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.13 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRDX indicates a rather cheap valuation: SRDX is cheaper than 86.53% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, SRDX is valued cheaply inside the industry as 91.71% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.31 | ||
| EV/EBITDA | 16.07 |
4.3 Compensation for Growth
SRDX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-99.21%
EPS Next 3Y-0.7%
5. Dividend
5.1 Amount
SRDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SURMODICS INC
NASDAQ:SRDX (5/15/2024, 2:56:06 PM)
33.75
+0.75 (+2.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap480.60M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.13 | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.39% | ||
| ROE | 10.9% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 13.5% | ||
| PM (TTM) | 9.45% | ||
| GM | 79.11% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.78
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.39 | ||
| Quick Ratio | 3.59 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)174.67%
EPS 3Y7.72%
EPS 5Y
EPS growth Q2Q
EPS Next Y-740.34%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)38.84%
Revenue growth 3Y11.79%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y